Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation

Pathobiology ◽  
2015 ◽  
Vol 82 (2) ◽  
pp. 76-83 ◽  
Author(s):  
Yoonjin Kwak ◽  
Soo Kyung Nam ◽  
An Na Seo ◽  
Duck-Woo Kim ◽  
Sung-Bum Kang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Copy Number ◽  
Fibroblast Growth Factor Receptor ◽  
Gene Copy Number ◽  
Growth Factor Receptor ◽  
Gene Copy ◽  
Fibroblast Growth ◽  
Primary Colorectal Cancer

Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer

2013 ◽  
Vol 31 (6) ◽  
pp. 731-737 ◽  
Author(s):  
Hye Ryun Kim ◽  
Dae Joon Kim ◽  
Dae Ryong Kang ◽  
Jin Gu Lee ◽  
Sun Min Lim ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cigarette Smoking ◽  
Fibroblast Growth Factor ◽  
Squamous Cell ◽  
Copy Number ◽  
Fibroblast Growth Factor Receptor ◽  
Gene Copy Number ◽  
Growth Factor Receptor ◽  
Gene Copy ◽  
Fibroblast Growth

Purpose To investigate the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma of the lung (SCCL) and the association between smoking and FGFR1 amplification. Patients and Methods Gene copy number of FGFR1 was investigated in microarrayed tumors from 262 patients with SCCL who had tumor tissue as well as smoking and survival data available. Gene copy number was evaluated by fluorescent in situ hybridization, and an FGFR1-amplified tumor (FGFR1 amp+) was prespecified as a tumor with nine or more copies of FGFR1. Results Among 262 patients, the frequency of FGFR1 amp+ was 13.0%. Patients with FGFR1 amp+ had significantly shorter disease-free survival (DFS; 26.9 v 94.6 months; P < .001) as well as shorter overall survival (OS; 51.2 v 115.0 months; P = .002) than those without FGFR1 amp+. Multivariate modeling confirmed that patients with FGFR1 amp+ had a significantly greater risk of recurrence and death than those without FGFR1 amp+ after adjusting for sex, smoking status, pathologic stage, and adjuvant chemotherapy (DFS: adjusted hazard ratio [AHR], 2.24; 95% CI, 1.45 to 3.45; P < .001; OS: AHR, 1.83; 95% CI, 1.15 to 2.89; P = .01). The frequency of FGFR1 amp+ was significantly higher in current smokers than in former smokers and never-smokers (28.9% v 2.5% v 0%; Ptrend < .001). As the smoking dosage increased, so did the incidence of FGFR1 amp+ (Ptrend = .002). Conclusion FGFR1 amplification is an independent negative prognostic factor in surgically resected SCCL and is associated with cigarette smoking in a dose-dependent manner. FGFR1 amplification is a relevant therapeutic target in Asian patients with SCCL.

Fibroblast Growth Factor Receptor-2 IIIc as a Novel Molecular Target in Colorectal Cancer

2013 ◽  
Vol 10 (1) ◽  
pp. 20-26
Author(s):  
Yoko Matsuda ◽  
Seiichi Shinji ◽  
Hisashi Yoshimura ◽  
Zenya Naito ◽  
Toshiyuki Ishiwata
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Molecular Target ◽  
Fibroblast Growth

Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer

Biomarkers ◽  
2014 ◽  
Vol 19 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Chen-Sheng Li ◽  
Shu-Xiang Zhang ◽  
Hong-Jun Liu ◽  
Yu-Long Shi ◽  
Le-Ping Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth

scholarly journals Fibroblast Growth Factor Receptor 2: Expression, Roles, and Potential As a Novel Molecular Target for Colorectal Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Yoko Matsuda ◽  
Junji Ueda ◽  
Toshiyuki Ishiwata
Keyword(s):  
Colorectal Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cancer Progression ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Type Iv ◽  
Well Differentiated ◽  
Novel Target

The fibroblast growth factor receptor (FGFR) family consists of four members, named FGFR1, 2, 3, and 4. All 4 FGFRs and their ligands, fibroblast growth factors (FGFs), are expressed in colorectal cancer (CRC). Recent studies have shown that FGFR2 plays important roles in cancer progression; therefore, it is of great interest as a novel target for cancers. Expression of FGFR2 regulates migration, invasion, and growth in CRC. Expression of the FGFR2 isoform FGFR2 IIIb was associated with well-differentiated histological types, and its specific ligand, FGF7, enhanced angiogenesis and adhesion to type-IV collagen via FGFR2 IIIb in CRC. FGFR2 IIIc is detected in CRC, but its roles have not been well elucidated. Interactions between FGFR2 IIIb and IIIc and FGFs may play important roles in CRC via autocrine and/or paracrine signaling. Several kinds of molecular-targeting agents against FGFR2 have been developed; however, it is not clear how a cancer treatment can most effectively inhibit FGFR2 IIIb or FGFR2 IIIc, or both isoforms. The aim of this paper is to summarize the roles of FGFR2 and its isoforms in CRC and clarify whether they are potent therapeutic targets for CRC.

Sign in / Sign up

Export Citation Format

Share Document